KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Free Cash Flow (2016 - 2025)

AbbVie (ABBV) has disclosed Free Cash Flow for 14 consecutive years, with $4.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 27.65% to $4.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $17.8 billion, a 0.09% change, with the full-year FY2025 number at $17.8 billion, changed 0.09% from a year prior.
  • Free Cash Flow was $4.9 billion for Q4 2025 at AbbVie, down from $6.6 billion in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $7.7 billion in Q3 2021 to a low of $1.4 billion in Q1 2025.
  • A 5-year average of $5.2 billion and a median of $4.9 billion in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 66.94% in 2024, then surged 140.59% in 2025.
  • AbbVie's Free Cash Flow stood at $4.9 billion in 2021, then soared by 47.61% to $7.2 billion in 2022, then crashed by 36.96% to $4.5 billion in 2023, then skyrocketed by 48.57% to $6.8 billion in 2024, then dropped by 27.65% to $4.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Free Cash Flow are $4.9 billion (Q4 2025), $6.6 billion (Q3 2025), and $4.9 billion (Q2 2025).